Crystec is a crystal and particle engineering company applying the latest supercritical fluid (SCF) techniques to enhance product performance. Our innovative technology allows substantial enhancement in the performance of molecules leading to strongly differentiated products. Outcomes that we are typically able to achieve include:- Decreased dose with equivalent levels of bioavailability - Enhanced stability- Improved dissolution rate of poorly soluble compounds- Faster onset of action- New routes of delivery (e.g. nasal/inhaled)- Combination particles (incorporating more than one API or API + enhancer)- Superior product performance in support of life cycle managementThe Crystec team consists of some the world’s leading scientists in the field of SCF technology based pharmaceutics, including Professor Peter York. Members of the Crystec team were also involved in the design and scale up of the world’s first SCF engineered drug (inhaled delivery for treatment of migraine) which is currently awaiting FDA approval (anticipated 2015).